|
1
|
Fock KM: Review article: The epidemiology
and prevention of gastric cancer. Aliment Pharmacol Ther.
40:250–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wadhwa R, Song S, Lee JS, Yao Y, Wei Q and
Ajani JA: Gastric cancer-molecular and clinical dimensions. Nat Rev
Clin Oncol. 10:643–655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wagner AD, Grothe W, Haerting J, Kleber G,
Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: A
systematic review and meta-analysis based on aggregate data. J Clin
Oncol. 24:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ji SH, Lim DH, Yi SY, Kim HS, Jun HJ, Kim
KH, Chang MH, Park MJ, Uhm JE, Lee J, et al: A retrospective
analysis of second-line chemotherapy in patients with advanced
gastric cancer. BMC Cancer. 9:1102009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wesolowski R, Lee C and Kim R: Is there a
role for second-line chemotherapy in advanced gastric cancer?
Lancet Oncol. 10:903–912. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wei J, Costa C, Ding Y, Zou Z, Yu L,
Sanchez JJ, Qian X, Chen H, Gimenez-Capitan A, Meng F, et al: mRNA
expression of BRCA1, PIAS1, and PIAS4 and survival after
second-line docetaxel in advanced gastric cancer. J Natl Cancer
Inst. 103:1552–1556. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang X, Fraser M, Moll UM, Basak A and
Tsang BK: Akt-mediated cisplatin resistance in ovarian cancer:
Modulation of p53 action on caspase-dependent mitochondrial death
pathway. Cancer Res. 66:3126–3136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yuan Z, Wang F, Zhao Z, Zhao X, Qiu J, Nie
C and Wei Y: BIM-mediated AKT phosphorylation is a key modulator of
arsenic trioxide-induced apoptosis in cisplatin-sensitive
and-resistant ovarian cancer cells. PLoS One. 6:e205862011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Asselin E, Mills GB and Tsang BK: XIAP
regulates Akt activity and caspase-3-dependent cleavage during
cisplatin-induced apoptosis in human ovarian epithelial cancer
cells. Cancer Res. 61:1862–1868. 2001.PubMed/NCBI
|
|
10
|
Jamieson ER and Lippard SJ: Structure,
recognition, and processing of cisplatin-DNA adducts. Chem Rev.
99:2467–2498. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alberti C: Taxane- and epothilone-based
chemotherapy: from molecule cargo cytoskeletal logistics to
management of castration-resistant prostate carcinoma. Eur Rev Med
Pharmacol Sci. 17:1658–1664. 2013.PubMed/NCBI
|
|
13
|
Zheng JH, Follis A Viacava, Kriwacki RW
and Moldoveanu T: Discoveries and controversies in BCL-2
protein-mediated apoptosis. FEBS J. 283:2690–2700. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Correia C, Lee SH, Meng XW, Vincelette ND,
Knorr KL, Ding H, Nowakowski GS, Dai H and Kaufmann SH: Emerging
understanding of Bcl-2 biology: Implications for neoplastic
progression and treatment. Biochim Biophys Acta. 1853:1658–1671.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iurlaro R and Muñoz-Pinedo C: Cell death
induced by endoplasmic reticulum stress. FEBS J. 283:2640–2652.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Crawford N, Chacko AD, Savage KI, McCoy F,
Redmond K, Longley DB and Fennell DA: Platinum resistant cancer
cells conserve sensitivity to BH3 domains and obatoclax induced
mitochondrial apoptosis. Apoptosis. 16:311–320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Simonin K, N'Diaye M, Lheureux S,
Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E,
Blanc-Fournier C and Poulain L: Platinum compounds sensitize
ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa
axis. Apoptosis. 18:492–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Inoue Y, Gika M, Abiko T, Oyama T, Saitoh
Y, Yamazaki H, Nakamura M, Abe Y, Kawamura M and Kobayashi K: Bcl-2
overexpression enhances in vitro sensitivity against docetaxel in
non-small cell lung cancer. Oncol Rep. 13:259–264. 2005.PubMed/NCBI
|
|
19
|
Savry A, Carre M, Berges R, Rovini A,
Pobel I, Chacon C, Braguer D and Bourgarel-Rey V: Bcl-2-enhanced
efficacy of microtubule-targeting chemotherapy through Bim
overexpression: Implications for cancer treatment. Neoplasia.
15:49–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Faber AC, Corcoran RB, Ebi H, Sequist LV,
Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, et
al: BIM expression in treatment-naive cancers predicts
responsiveness to kinase inhibitors. Cancer Discov. 1:352–365.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Costa C, Molina MA, Drozdowskyj A,
Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R,
Massuti B, Wei J, Moran T, et al: The impact of EGFR T790M
mutations and BIM mRNA expression on outcome in patients with
EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the
randomized phase III EURTAC trial. Clin Cancer Res. 20:2001–2010.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao
W, Volsky DJ and Fisher PB: Identification and cloning of human
astrocyte genes displaying elevated expression after infection with
HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid
subtraction hybridization, RaSH. Oncogene. 21:3592–3602. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu G, Wei Y and Kang Y: The multifaceted
role of MTDH/AEG-1 in cancer progression. Clin Cancer Res.
15:5615–5620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee SG, Su ZZ, Emdad L, Sarkar D, Franke
TF and Fisher PB: Astrocyte elevated gene-1 activates cell survival
pathways through PI3K-Akt signaling. Oncogene. 27:1114–1121. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jian-bo X, Hui W, Yu-long H, Chang-hua Z,
Long-juan Z, Shi-rong C and Wen-hua Z: Astrocyte-elevated gene-1
overexpression is associated with poor prognosis in gastric cancer.
Med Oncol. 28:455–462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song L, Li W, Zhang H, Liao W, Dai T, Yu
C, Ding X, Zhang L and Li J: Over-expression of AEG-1 significantly
associates with tumour aggressiveness and poor prognosis in human
non-small cell lung cancer. J Pathol. 219:317–326. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoo BK, Gredler R, Vozhilla N, Su ZZ, Chen
D, Forcier T, Shah K, Saxena U, Hansen U, Fisher PB and Sarkar D:
Identification of genes conferring resistance to 5-fluorouracil.
Proc Natl Acad Sci USA. 106:12938–12943. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Santarpia M, Magri I, Sanchez-Ronco M,
Costa C, Molina-Vila MA, Gimenez-Capitan A, Bertran-Alamillo J,
Mayo C, Benlloch S, Viteri S, et al: mRNA expression levels and
genetic status of genes involved in the EGFR and NF-.
|
|
29
|
B pathways in metastatic non-small-cell
lung cancer patients. J Transl Med. 9:1632011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Graham DK, DeRyckere D, Davies KD and Earp
HS: The TAM family: Phosphatidylserine sensing receptor tyrosine
kinases gone awry in cancer. Nat Rev Cancer. 14:769–785. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
van der Meer JH, van der Poll T and van 't
Veer C: TAM receptors, Gas6, and protein S: roles in inflammation
and hemostasis. Blood. 123:2460–2469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Papadakis ES, Cichoń MA, Vyas JJ, Patel N,
Ghali L, Cerio R, Storey A and O'Toole EA: Axl promotes cutaneous
squamous cell carcinoma survival through negative regulation of
pro-apoptotic Bcl-2 family members. J Invest Dermatol. 131:509–517.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Verma A, Warner SL, Vankayalapati H,
Bearss DJ and Sharma S: Targeting Axl and Mer kinases in cancer.
Mol Cancer Ther. 10:1763–1773. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ou WB, Corson JM, Flynn DL, Lu WP, Wise
SC, Bueno R, Sugarbaker DJ and Fletcher JA: AXL regulates
mesothelioma proliferation and invasiveness. Oncogene.
30:1643–1652. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wimmel A, Glitz D, Kraus A, Roeder J and
Schuermann M: Axl receptor tyrosine kinase expression in human lung
cancer cell lines correlates with cellular adhesion. Eur J Cancer.
37:2264–2274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Berclaz G, Altermatt HJ, Rohrbach V,
Kieffer I, Dreher E and Andres AC: Estrogen dependent expression of
the receptor tyrosine kinase axl in normal and malignant human
breast. Ann Oncol. 12:819–824. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Macleod K, Mullen P, Sewell J, Rabiasz G,
Lawrie S, Miller E, Smyth JF and Langdon SP: Altered ErbB receptor
signaling and gene expression in cisplatin-resistant ovarian
cancer. Cancer Res. 65:6789–6800. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bubner B and Baldwin IT: Use of real-time
PCR for determining copy number and zygosity in transgenic plants.
Plant Cell Rep. 23:263–271. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Elimova E, Shiozaki H, Wadhwa R, Sudo K,
Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S and Ajani
JA: Medical management of gastric cancer: A 2014 update. World J
Gastroenterol. 20:13637–13647. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wei J, Costa C, Shen J, Yu L, Sanchez J,
Qian X, Sun X, Zou Z, Gimenez-Capitan A, Yue G, et al: Differential
effect of MMSET mRNA levels on survival to first-line FOLFOX and
second-line docetaxel in gastric cancer. Br J Cancer.
110:2662–2668. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pan ST, Li ZL, He ZX, Qiu JX and Zhou SF:
Molecular mechanisms for tumour resistance to chemotherapy. Clin
Exp Pharmacol Physiol. 43:723–737. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cree IA and Charlton P: Molecular chess?
Hallmarks of anti-cancer drug resistance. BMC cancer. 17:102017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chang JC, Wooten EC, Tsimelzon A,
Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK,
Chamness GC, Allred DC and O'Connell P: Gene expression profiling
for the prediction of therapeutic response to docetaxel in patients
with breast cancer. Lancet. 362:362–369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kang BW, Kwon OK, Chung HY, Yu W and Kim
JG: Taxanes in the rreatment of advanced gastric cancer. Molecules.
21:E6512016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Costa DB, Halmos B, Kumar A, Schumer ST,
Huberman MS, Boggon TJ, Tenen DG and Kobayashi S: BIM mediates EGFR
tyrosine kinase inhibitor-induced apoptosis in lung cancers with
oncogenic EGFR mutations. PLoS Med. 4:1669–1680. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gong Y, Somwar R, Politi K, Balak M,
Chmielecki J, Jiang X and Pao W: Induction of BIM is essential for
apoptosis triggered by EGFR kinase inhibitors in mutant
EGFR-dependent lung adenocarcinomas. PLoS Med. 4:e2942007.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kuroda J, Puthalakath H, Cragg MS, Kelly
PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ,
Villunger A, et al: Bim and Bad mediate imatinib-induced killing of
Bcr/Abl+ leukemic cells, and resistance due to their
loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA.
103:14907–14912. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Qi XJ, Wildey GM and Howe PH: Evidence
that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL
apoptotic function. J Biol Chem. 281:813–823. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Brown JS and Banerji U: Maximising the
potential of AKT inhibitors as anti-cancer treatments. Pharmacol
Ther. December 2–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sun Y, Tian H, Wang L and Yang H: The
effects of silencing of PI3K p85α on 5-FU-induced colorectal cancer
cells apoptosis. Med Oncol. 30:7042013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Carbajo-Pescador S, Mauriz JL,
García-Palomo A and González-Gallego J: FoxO proteins: Regulation
and molecular targets in liver cancer. Curr Med Chem. 21:1231–1246.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
de Mattos S Fernández, Villalonga P,
Clardy J and Lam EW: FOXO3a mediates the cytotoxic effects of
cisplatin in colon cancer cells. Mol Cancer Ther. 7:3237–3246.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Vogiatzi P, De Falco G, Claudio PP and
Giordano A: How does the human RUNX3 gene induce apoptosis in
gastric cancer? Latest data, reflections and reactions. Cancer Biol
Ther. 5:371–374. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Piñon JD, Labi V, Egle A and Villunger A:
Bim and Bmf in tissue homeostasis and malignant disease. Oncogene.
27:(Suppl 1). S41–S52. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sunters A, de Mattos S Fernández, Stahl M,
Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH,
Coombes RC and Lam EW: FoxO3a transcriptional regulation of Bim
controls apoptosis in paclitaxel-treated breast cancer cell lines.
J Biol Chem. 278:49795–49805. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hu G, Wei Y and Kang Y: The multifaceted
role of MTDH/AEG-1 in cancer progression. Clin Cancer Res.
15:5615–5620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wilson MS, Brosens JJ, Schwenen HD and Lam
EW: FOXO and FOXM1 in cancer: The FOXO-FOXM1 axis shapes the
outcome of cancer chemotherapy. Curr Drug Targets. 12:1256–1266.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lemke G: Biology of the TAM receptors.
Cold Spring Harb Perspect Biol. 5:a0090762013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li Y, Jia L, Ren D, Liu C, Gong Y, Wang N,
Zhang X and Zhao Y: Axl mediates tumor invasion and
chemosensitivity through PI3K/Akt signaling pathway and is
transcriptionally regulated by slug in breast carcinoma. IUBMB
Life. 66:507–518. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hasanbasic I, Cuerquis J, Varnum B and
Blostein MD: Intracellular signaling pathways involved in
Gas6-Axl-mediated survival of endothelial cells. Am J Physiol Heart
Circ Physiol. 287:H1207–H1213. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Goruppi S, Ruaro E, Varnum B and Schneider
C: Gas6-mediated survival in NIH3T3 cells activates stress
signalling cascade and is independent of Ras. Oncogene.
18:4224–4236. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Holland SJ, Powell MJ, Franci C, Chan EW,
Friera AM, Atchison RE, McLaughlin J, Swift SE, Pali ES, Yam G, et
al: Multiple roles for the receptor tyrosine kinase axl in tumor
formation. Cancer Res. 65:9294–9303. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Tjwa M, Bellido-Martin L, Lin Y, Lutgens
E, Plaisance S, Bono F, Delesque-Touchard N, Hervé C, Moura R,
Billiau AD, et al: Gas6 promotes inflammation by enhancing
interactions between endothelial cells, platelets, and leukocytes.
Blood. 111:4096–4105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hu G, Chong RA, Yang Q, Wei Y, Blanco MA,
Li F, Reiss M, Au JL, Haffty BG and Kang Y: MTDH activation by 8q22
genomic gain promotes chemoresistance and metastasis of
poor-prognosis breast cancer. Cancer Cell. 15:9–20. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li C, Li Y, Wang X, Wang Z, Cai J, Wang L,
Zhao Y, Song H, Meng X, Ning X, et al: Elevated expression of
astrocyte elevated gene-1 (AEG-1) is correlated with
cisplatin-based chemoresistance and shortened outcome in patients
with stages III–IV serous ovarian carcinoma. Histopathology.
60:953–963. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Hong J, Peng D, Chen Z, Sehdev V and
Belkhiri A: ABL regulation by AXL promotes cisplatin resistance in
esophageal cancer. Cancer Res. 73:331–340. 2013. View Article : Google Scholar : PubMed/NCBI
|
